Skip to main content Accessibility help
×
Home
  • Print publication year: 2009
  • Online publication date: August 2010

32 - Epidemiology of sleep medication use in the elderly

from Part 4 - Treatment of sleep disorders in the elderly

Summary

This chapter reviews the clinical and polysomnographic features of elderly narcoleptic subjects, and considers co-morbidity and therapeutic issues. A number of narcoleptic patients are older than 40 at diagnosis, this being due either to mild disease severity or misdiagnosis, or diagnosis delayed until late-life expression of cataplexy, or narcolepsy lacking cataplexy. Knowledge about the co-morbid disorders in narcolepsy is important inasmuch as it may sometimes contribute to diagnosis and it may also bring some insights into the pathophysiology of narcolepsy. Among the most frequently associated diseases were parasomnias, sleep-related breathing disorders, sleep-related movement disorders, internistic diseases, neurological disorders, and psychiatric disorders. Moreover, various drugs, such as stimulants, antidepressants, and sodium oxybate used in narcolepsy have been tested in adult patients over a range of ages, but not specifically in elderly subjects.

Related content

Powered by UNSILO

References

1. Wikipedia. Laudanum. http://en.wikipedia.org/wiki/Laudanum.
2. Wikipedia. Bromide. http://en.wikipedia.org/wiki/Bromide.
3. NeutelCI, WalopW, AppelCW. Triazolam and the potential for violence: the need for an epidemiological study. Can Pharm J 1992;216:214–7.
4. LiebermanJA. Update on the safety considerations in the management of insomnia with hypnotics: incorporating modified-release formulations into primary care. Prim Care Companion J Clin Psychiatry 2007;9(1):25–31.
5. WagnerJ, WagnerML. Non-benzodiazepines for the treatment of insomnia. Sleep Med Rev 2000;4:551–81.
6. BellonA. Searching for new options for treating insomnia: are melatonin and ramelteon beneficial?J Psychiatr Pract 2006;12(4):229–43.
7. RoehrsT, RothT. Sleep, sleepiness and alcohol use. Alcohol Res Health 2001;25(2):101–9.
8. RoehrsT, HollebeekE, DrakeC, RothT. Substance use for insomnia in Metropolitan Detroit. J Psychosom Res 2002;53(1):571–6.
9. RoehrsT, BurduvaliE, BonahoomA, DrakeC, RothT. Ethanol and sleep loss: a “dose” comparison of impairing effects. Sleep 2003;26(8):981–5.
10. WHO Collaborating Centre for Drug Statistics Methodology/Nordic Council on Medicines. Guidelines for ATC Classification. Oslo, 1990.
11. Patented Medicine Prices Review Board. ATC Classification System for Human Medicines. Ottawa: Patented Medicine Prices Review Board; 1994.
12. WalopW, SemenchukM. Coding of drugs used by respondents of the Canadian study of health and aging. Can J Clin Pharmacol 2002;9:64–8.
13. NeutelCI. The epidemiology of long-term benzodiazepine use. Int Rev Psychiatry 2005;17(3):189–97.
14. BustoUE, SprouleBA, KnightK, HerrmannN. Use of prescription and nonprescription hypnotics in a Canadian elderly population. Can J Clin Pharmacol 2001;8(4):213–21.
15. BarbuiC, GregisM, ZappaM. A cross-sectional audit of benzodiazepine use among general practice patients. Acta Psychiatr Scand 1998;97:153–6.
16. BalkrishnanR, RasuRS, RajagopalanR. Physician and patient determinants of pharmacologic treatment of sleep difficulties in outpatient settings in the United States. Sleep 2005;28(6):715–19.
17. OhayonMM, CauletM. Insomnia and psychotropic drug consumption. Prog Neuropsychopharmacol Biol Psychiatry 1995;19(3):421–31.
18. FourrierA, LetenneurL, DartiguesJF, MooreN, BegaudB. Benzodiazepine use in an elderly community-dwelling population: characteristics of users and factors associated with subsequent use. Eur J Pharmacol 2001;57:419–25.
19. NeutelCI, WalopW. Drug utilization by men and women: why the difference?Drug Inf J 2005;39:299–310.
20. RothT, RoehrsT. Insomnia: epidemiology, characteristics, and consequences. Clin Cornerstone 2003;5(3):5–15.
21. BarbuiC, CampomoriA, MezzaliraL, et al. Psychotropic drug use in Italy, 1984–1999: the impact of a change in reimbursement status. Int Clin Psychopharmacol 2001;16:227–33.
22. MendelsonWB, RothT, CassellaJ, et al. The treatment of chronic insomnia: drug indications, chronic use and abuse liability: summary of a 2001 New Clinical Drug Evaluation Unit meeting symposium. Sleep Med Rev 2004;8:7–17.
23. OhayonMM, CauletM. Psychotropic medication and insomnia complaints in two epidemiological studies. Can J Psychiatry 1996;41(7):457–64.
24. BencaRM. Diagnosis and treatment of chronic insomnia: a review. Psychiatr Serv 2005;56(3):332–43.
25. Ancoli-IsraelS, PocetaJS, StepnowskyC, MartinJ, GehrmanP. Identification and treatment of sleep problems in the elderly. Sleep Med Rev 1997;1(1):3–17.
26. ShochatT, LoredoJ, Ancoli-IsraelS. Sleep disorders in the elderly. Curr Treat Options Neurol 2001;3(1):19–36.
27. RoehrsT, RothT. Sleep and pain: interaction of two vital functions. Semin Neurol 2005;25(1):106–16.
28. TuK, MamdaniMM, HuxJE, TuJB. Progressive trends in the prevalence of benzodiazepine prescribing in older people in Ontario, Canada. J Am Geriatr Soc 2001;49(10):1341–5.
29. BartlettG, AbrahamowiczM, TamblynR, et al. Longitudinal patterns of new benzodiazepine use in the elderly. Pharmacoepidemiol Drug Saf 2004;13(10):669–82.
30. TuK, MamdaniMM, HuxJE, TuJB. Progressive trends in the prevalence of benzodiazepine prescribing in older people in Ontario, Canada. J Am Geriatr Soc 2001;49:1341–5.
31. LaderM. Zopiclone: is there any dependence and abuse potential?J Neurol 1997;244(4 Suppl. 1):S18–22.
32. SchweizerE, RickelsK, CaseWG, GreenblattDJ. Long-term therapeutic use of benzodiazepines. II. Effects of gradual taper. Arch Gen Psychiatry 1990;47:908–15.
33. BustoU, SellersEM, NaranjoCA, et al. Withdrawal reaction after long-term therapeutic use of benzodiazepines. N Engl J Med 1986;315:854–9.
34. RickelsK, SchweizerE, CaseWG, GreenblattDJ. Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. Arch Gen Psychiatry 1990;47:899–907.
35. HajakG, ClarenbachP, FisherW, et al. Rebound insomnia after hypnotic withdrawal in insomniac outpatients. Eur Arch Psychiatry Clin Neurosci 1998;248:148–56.
36. BustoU, SellersEM. Pharmacological aspects of benzodiazepine tolerance and dependence. J Subst Abuse Treat 1991;8:29–33.
37. BatesonAN. Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal. Curr Pharm Des 2002;8:5–21.
38. BarterG, CormackM. The long-term use of benzodiazepines: patients’ views, accounts and experiences. Fam Pract 1996;13:491–7.
39. SprouleBA, BustoUE, BuckleC, HerrmannN, BowlesS. The use of non-prescription sleep products in the elderly. Int J Geriatr Psychiatry 1999;14(10):851–7.
40. MahL, UpshurRE. Long term benzodiazepine use for insomnia in patients over the age of 60: discordance of patient and physician perceptions. BMC Fam Pract 2002;3:9–15.
41. LindenM, BarT, GeiselmannB. Patient treatment insistence and medication craving in long-term low-dosage benzodiazepine prescriptions. Psychol Med 1998;28:721–9.
42. WinkelmanJ, PiesR. Current patterns and future directions in the treatment of insomnia. Ann Clin Psychiatry 2005;17(1):31–40.
43. JeffersonCD, DrakeCL, ScofieldHM, et al. Sleep hygiene practices in a population-based sample of insomniacs. Sleep 2005;28(5):611–5.
44. DamestoyN, CollinJ, LalandeR. Prescribing psychotropic medication for elderly patients: some physicians’ perspectives. Can Med Assoc J 1999;161:143–5.
45. PimlottNJ, HuxJE, WilsonLM, et al. Educating physicians to reduce benzodiazepine use by elderly patients: a randomized controlled trial. CMAJ 2003;168:835–9.
46. McNuttLA, ColesFB, McAuliffeT, et al. Impact of regulation on benzodiazepine prescribing to a low income elderly population, New York State. J Clin Epidemiol 1994;47(6):613–25.
47. WeintraubM, SinghS, ByrneL, MaharajiK, GuttmacherL. Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations. JAMA 1991;266:2392–7.
48. ZullichSG, GraselaTH Jr, Fiedler-KellyJB, GengoFM. Impact of triplicate prescription program in psychotropic prescribing patterns in long-term care facilities. Ann Pharmacother 1992;26:539–46.
49. MendelsonWB, JainB. An assessment of short-acting hypnotics. Drug Saf 1995;13(4):257–70.
50. HolbrookAM, CrowtherR, LotterA, ChengC, KingD. The diagnosis and management of insomnia in clinical practice: a practical evidence-based approach. CMAJ 2000;162(2):216–20.